Research & Development
Research
Acura is engaged in the research of technologies to provide abuse deterrent features and benefits to abused pharmaceutical products. Products such as opioid analgesics like morphine, oxycodone, and hydrocodone and benzodiazepines like alprazolam and diazepam developed utilizing our Aversion® Technology are intended to effectively relieve pain while simultaneously discouraging common methods of pharmaceutical product misuse and abuse including:
- intravenous injection of dissolved tablets or capsules
- nasal snorting of crushed tablets or capsules
- intentional swallowing of excess quantities of tablets or capsules
Acura has begun initial laboratory testing of a new product candidate developed with our novel Impede™ Technology. Impede™ Technology is primarily intended to inhibit the conversion of pseudoephedrine HCl (a legally available nasal decongestant) into methamphetamine (an illicit and frequently abused drug).
Development
Acura’s innovative Aversion® Technology platform has been successfully utilized in developing multiple opioid analgesic product candidates. Development of Acurox® Tablets, our lead product candidate, is supported by numerous laboratory studies and statistically significant and clinically meaningful Phase II and Phase III study results. Additional product candidates in development are supported by laboratory and bioequivalence studies.
We believe that the application of Aversion® Technology to non-opioid abused products may have a similar regulatory process and could result in a significant market opportunity for us.
Manufacturing
Acura manufactures clinical trial supplies of drug products at our Culver facility in volumes sufficient to meet U.S. Food and Drug Administration standards for New Drug Applications.
